Regarding the histology in the PD-L1-positive population, the benefit in terms of survival derived from pembrolizumab derived benefit in CPS ≥ 10 population seemed to be higher in the ESCC, with a median OS of 10.3 months vs. 6.7 months, whereas mOS was 6.3 months vs. 6.9 months in EAC, although this last component ranked around only 25% of this selected subgroup. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.